Aging is something that we all have to go through. Or at least we thought it was before tech CEOs started investing billions of dollars in anti-aging and longevity research start-ups. Sam Altman of ChatGPT fame turned out to be the mysterious $180 million investor that kickstarted Retro Sciences’ research on the topic.
A biotech company based in Silicon Valley, Retro Biosciences has taken on the mission of adding 10 more years to human life and they are planning to do so by using their collective knowledge of cellular reprogramming, autophagy, and plasma-inspired therapeutics. But they have an ace up their sleeve. They are going to use machine-learning-based computational biology and lab automation to help with the project. This must’ve sparked the interest of the OpenAI CEO if he went on to invest a good chunk of his liquid net worth in the project. This is not the first case of a tech billionaire investing in longevity and anti-aging.
Jeff Bezos himself has also invested in a similar company called Alton Labs, a research company focused on cellular rejuvenation programming. Is life extension an industry that will be lucrative soon or are Silicon Valley eccentrics just fighting an uphill battle to beat mortality and human nature? We might find out sooner than we thought.
#chatgpt #samaltman.
Join our YouTube channel by clicking here: https://bit.ly/3asNo2n.
Find us on Instagram: https://bit.ly/3PM21xW
Find us on Facebook: https://bit.ly/3t2Huvb.
Find us on Twitter: https://bit.ly/3wQfXzA
Find us on TikTok: https://bit.ly/3wNsBOu.
Get the latest stories: https://interestingengineering.com/
Comments are closed.